Catherine Elisabeth Charron

This inventor holds 21 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 10 EPO patents, primarily in P38 MAP Kinase Inhibitors. Top assignees: Respivert Limited, Topivert Pharma Limited. Active years: 2012-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Catherine Elisabeth Charron. Retrieved from https://idiyas.com/inventor/catherine-elisabeth-charron

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 7)

% Patents Active = 90.5

CIPO Patents = 2

EPO Patents = 10 (Patent Applications = 11)

Average Co-Inventor Count = 7.4

ph-index = 11

Forward Citations = 398(Granted Patents)

Company Filing History:

Topivert Pharma Limited

patents

where one patent can have more than one assignee

Years Active: 2012-2020

Loading Chart...

Areas of Expertise:

P38 MAP Kinase

Inhibitors

Pyrazole Derivatives

Kinase Inhibitors

Ureas

Anilinopyrimidin

Naphthalenes

Chemical Compounds

Pharmaceuticals

Drug Development

Biochemistry

Medicinal Chemistry

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10813932 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors (2020-10-27),

2. 10738032 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors (2020-08-11),

3. 10266519 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors (2019-04-23),

4. 10238658 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors (2019-03-26),

5. 10144721 - P38 MAP kinase inhibitors (2018-12-04),

6. 9993478 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors (2018-06-12),

7. 9850231 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors (2017-12-26),

8. 9724347 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors (2017-08-08),

9. 9701670 - Pyrazolyl-ureas as kinase inhibitors (2017-07-11),

10. 9475796 - 1-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors (2016-10-25),

11. 9260410 - P38 MAP kinase inhibitors (2016-02-16),

12. 9249125 - Pyrazole derivatives as p38 MAP inhibitors (2016-02-02),

13. 9242960 - P38MAP kinase inhibitors (2016-01-26),

14. 9108950 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors (2015-08-18),

15. 8975285 - P38 MAP kinase inhibitors (2015-03-10),

Title: Catherine Elisabeth Charron: Innovator in Pharmaceutical Development

Catherine Elisabeth Charron is a prominent inventor based in London, GB, holding an impressive portfolio of 21 patents. Her work primarily focuses on innovative therapeutic solutions, particularly in the field of inflammatory diseases.

Latest Patents

Among her latest contributions to the scientific community are patents for compounds known as 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) naphthalen-1-yl) ureas, which serve as inhibitors of the p38 mitogen-activated protein kinase family. These compounds are significant for their therapeutic applications in treating inflammatory diseases, including respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD). The patent highlights the potential use of these inhibitors in pharmaceutical combinations to enhance therapy.

Career Highlights

Catherine has garnered extensive experience in the pharmaceutical industry, having worked with notable companies like Respivert Limited and Topivert Pharma Limited. Her role in these organizations has contributed significantly to the advancement of innovative treatments targeting inflammatory responses in human health.

Collaborations

Throughout her career, Catherine has collaborated with other brilliant minds in the industry. Notable coworkers include John King-Underwood and Stuart Thomas Onions, with whom she has shared insights and knowledge to advance their collective research and development efforts.

Conclusion

Catherine Elisabeth Charron's dedication to innovation in therapeutic development and her extensive patent portfolio underscore her valuable contributions to the pharmaceutical industry. Her work continues to impact the treatment of inflammatory diseases, paving the way for more effective healthcare solutions.

Profile summary based on public USPTO records.